These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 19747426)

  • 41. Active, phosphorylation-dependent mitogen-activated protein kinase (MAPK/ERK), stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK), and p38 kinase expression in Parkinson's disease and Dementia with Lewy bodies.
    Ferrer I; Blanco R; Carmona M; Puig B; Barrachina M; Gómez C; Ambrosio S
    J Neural Transm (Vienna); 2001; 108(12):1383-96. PubMed ID: 11810403
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparisons of clinical symptoms in biomarker-confirmed Alzheimer's disease, dementia with Lewy bodies, and frontotemporal dementia patients in a local memory clinic.
    Shea YF; Ha J; Chu LW
    Psychogeriatrics; 2015 Dec; 15(4):235-41. PubMed ID: 25533477
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders.
    Hall S; Öhrfelt A; Constantinescu R; Andreasson U; Surova Y; Bostrom F; Nilsson C; Håkan W; Decraemer H; Någga K; Minthon L; Londos E; Vanmechelen E; Holmberg B; Zetterberg H; Blennow K; Hansson O
    Arch Neurol; 2012 Nov; 69(11):1445-52. PubMed ID: 22925882
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Glial fibrillar acidic protein in the cerebrospinal fluid of Alzheimer's disease, dementia with Lewy bodies, and frontotemporal lobar degeneration.
    Ishiki A; Kamada M; Kawamura Y; Terao C; Shimoda F; Tomita N; Arai H; Furukawa K
    J Neurochem; 2016 Jan; 136(2):258-61. PubMed ID: 26485083
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dementia with Lewy bodies.
    McKeith IG; Burn DJ; Ballard CG; Collerton D; Jaros E; Morris CM; McLaren A; Perry EK; Perry R; Piggott MA; O'Brien JT
    Semin Clin Neuropsychiatry; 2003 Jan; 8(1):46-57. PubMed ID: 12567332
    [TBL] [Abstract][Full Text] [Related]  

  • 46. CSF synuclein: adding to the biomarker footprint of dementia with Lewy bodies.
    Mollenhauer B; Schlossmacher MG
    J Neurol Neurosurg Psychiatry; 2010 Jun; 81(6):590-1. PubMed ID: 20522867
    [No Abstract]   [Full Text] [Related]  

  • 47. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies.
    Baba M; Nakajo S; Tu PH; Tomita T; Nakaya K; Lee VM; Trojanowski JQ; Iwatsubo T
    Am J Pathol; 1998 Apr; 152(4):879-84. PubMed ID: 9546347
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies.
    Parnetti L; Tiraboschi P; Lanari A; Peducci M; Padiglioni C; D'Amore C; Pierguidi L; Tambasco N; Rossi A; Calabresi P
    Biol Psychiatry; 2008 Nov; 64(10):850-5. PubMed ID: 18395699
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cerebrospinal Fluid Total and Phosphorylated α-Synuclein in Patients with Creutzfeldt-Jakob Disease and Synucleinopathy.
    Schmitz M; Villar-Piqué A; Llorens F; Gmitterová K; Hermann P; Varges D; Zafar S; Lingor P; Vanderstichele H; Demeyer L; Stoops E; Trojanowski JQ; Lee VM; Zerr I
    Mol Neurobiol; 2019 May; 56(5):3476-3483. PubMed ID: 30136097
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cerebrospinal fluid markers in dementia with lewy bodies compared with Alzheimer disease.
    Gómez-Tortosa E; Gonzalo I; Fanjul S; Sainz MJ; Cantarero S; Cemillán C; Yébenes JG; del Ser T
    Arch Neurol; 2003 Sep; 60(9):1218-22. PubMed ID: 12975286
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Serum heart-type fatty acid-binding protein and cerebrospinal fluid tau: marker candidates for dementia with Lewy bodies.
    Mollenhauer B; Steinacker P; Bahn E; Bibl M; Brechlin P; Schlossmacher MG; Locascio JJ; Wiltfang J; Kretzschmar HA; Poser S; Trenkwalder C; Otto M
    Neurodegener Dis; 2007; 4(5):366-75. PubMed ID: 17622779
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Amyloid pathology influences aβ1-42 cerebrospinal fluid levels in dementia with lewy bodies.
    Slaets S; Le Bastard N; Theuns J; Sleegers K; Verstraeten A; De Leenheir E; Luyckx J; Martin JJ; Van Broeckhoven C; Engelborghs S
    J Alzheimers Dis; 2013; 35(1):137-46. PubMed ID: 23364139
    [TBL] [Abstract][Full Text] [Related]  

  • 53. DNA methylation changes at SNCA intron 1 in patients with dementia with Lewy bodies.
    Funahashi Y; Yoshino Y; Yamazaki K; Mori Y; Mori T; Ozaki Y; Sao T; Ochi S; Iga JI; Ueno SI
    Psychiatry Clin Neurosci; 2017 Jan; 71(1):28-35. PubMed ID: 27685250
    [TBL] [Abstract][Full Text] [Related]  

  • 54. α-Synuclein mRNA and soluble α-synuclein protein levels in post-mortem brain from patients with Parkinson's disease, dementia with Lewy bodies, and Alzheimer's disease.
    Quinn JG; Coulson DT; Brockbank S; Beyer N; Ravid R; Hellemans J; Irvine GB; Johnston JA
    Brain Res; 2012 Jun; 1459():71-80. PubMed ID: 22560502
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Differential expression of alpha-synuclein isoforms in dementia with Lewy bodies.
    Beyer K; Lao JI; Carrato C; Mate JL; López D; Ferrer I; Ariza A
    Neuropathol Appl Neurobiol; 2004 Dec; 30(6):601-7. PubMed ID: 15541000
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Decreased α-synuclein serum levels in patients with Lewy body dementia compared to Alzheimer's disease patients and control subjects.
    Laske C; Fallgatter AJ; Stransky E; Hagen K; Berg D; Maetzler W
    Dement Geriatr Cogn Disord; 2011; 31(6):413-6. PubMed ID: 21757905
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Validation of amyloid-beta peptides in CSF diagnosis of neurodegenerative dementias.
    Bibl M; Mollenhauer B; Lewczuk P; Esselmann H; Wolf S; Trenkwalder C; Otto M; Stiens G; Rüther E; Kornhuber J; Wiltfang J
    Mol Psychiatry; 2007 Jul; 12(7):671-80. PubMed ID: 17339876
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Detection of disease-associated α-synuclein in the cerebrospinal fluid: a feasibility study.
    Unterberger U; Lachmann I; Voigtländer T; Pirker W; Berghoff AS; Flach K; Wagner U; Geneste A; Perret-Liaudet A; Kovacs GG
    Clin Neuropathol; 2014; 33(5):329-34. PubMed ID: 25131945
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Erythrocytes as Biomarkers for Dementia: Analysis of Protein Content and Alpha-Synuclein.
    Graham C; Santiago-Mugica E; Abdel-All Z; Li M; McNally R; Kalaria RN; Mukaetova-Ladinska EB
    J Alzheimers Dis; 2019 Aug; 71(2):569-580. PubMed ID: 31424413
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Low-abundant cerebrospinal fluid proteome alterations in dementia with Lewy bodies.
    Dieks JK; Gawinecka J; Asif AR; Varges D; Gmitterova K; Streich JH; Dihazi H; Heinemann U; Zerr I
    J Alzheimers Dis; 2013; 34(2):387-97. PubMed ID: 23254635
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.